Thx for the big picture ips, makes me think about how BTX was $30 in 1997 when Wired Magazine hyped their Hextend product and its cryo freezing capabilities. At that time they were a COMPLETELY different company in that they had not yet entered into the stem cell arena. The good news is that unlike 1997 Biotime has like you said built a company on eight years of solid R&D that has opened up new avenues. Who would have thought they would evolve into what looks like a cancer sector powerhouse.
Unlike the Hextend days Biotime is built on a solid foundation of technologies including a worldwide monopoly on the gold standard hESC progenitor ip. If you look at the full chart of BTX you'll notice they were around $30 in 1997 and only a matter of time before they wiz past that high point when we were a shell of a company..
BB, being that you have played BTX for close to a decade, I trust you keep on coming back as you have trust in Dr. west and the empire he has built. What do you think of Cancer diagnostics PanC-DX and do you think OncoCyte will make as successful IPO as AST has been?
Knowing Dr West's biz savvy, he will time a major milestone as we dip over the next days/week.
Both LifeMap and PanC-DX marketing plans to be unveiled soon, IMO, this will take us to the next level of $6-8, and that might be low balling it.
OncoCyte IPO will be great, do you think West would sell right off the bat to big pharma or maybe sell to AST!
Jepro, pumper?..no just a simple fact, BTX releases to market next-gen cancer diagnostic products by end of 2015 and stock triples from current price. And again PanC-DX is low hanging fruit that will before long pull in billions paving the way for Biotimes stem cell regen products that will revolutionize medicine. Within 5 years BTX's off the shelf cartilage/tendon regen products will begin supplying the NFL, NBA and other sports leagues around the world.
Pumper, no just a very informed investor
Double if not triple. Volume will shoot up as will stock price when the average investor hears BTX next-gen cancer diagnostic products hit the market in late 2015.
And when this happens BTX will then have the $ to push heart, cartilage and other regen therapies forward. Once in a life time here.
This kind of next gen regen therapy will be on BTX front burner in 6 mo after cancer diagnostic products and genetic medical app start their marketing phase.
To bb and his other alias shorters: NOT getting my shares!
After 7 years of R&D we acquired the worlds best IP......liftoff commencing!
Will be one of the most extensive/cutting edge genetic medical apps to hit the market. Very cool!